<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959786</url>
  </required_header>
  <id_info>
    <org_study_id>mu-med-2020-26</org_study_id>
    <nct_id>NCT04959786</nct_id>
  </id_info>
  <brief_title>MANS-NRIZ Trial for COVID-19 Treatment : Extension Study</brief_title>
  <official_title>Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This search will focus on patients with COVID 19 infection this study is a prospective cohort&#xD;
      study based on the analysis of response in comparative panel between two arm Nitazoxanide,&#xD;
      Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the&#xD;
      safety and efficacy and cost effective result. Two years duration of the project would be&#xD;
      enough to cover the stages of the work as shown below in the time plan. Initial stage of&#xD;
      collecting materials and patients' clinical data, each patient will undergoes strict follow&#xD;
      up period to reveal the clinical, laboratory and radiological response. The procedures are to&#xD;
      be approved by the institutional ethical committee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This search will focus on patients with COVID 19 infection this study is a prospective cohort&#xD;
      study based on the analysis of response in comparative panel between two arm Nitazoxanide,&#xD;
      Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the&#xD;
      safety and efficacy and cost effective result. Two years duration of the project would be&#xD;
      enough to cover the stages of the work as shown below in the time plan. Initial stage of&#xD;
      collecting materials and patients' clinical data, each patient will undergoes strict follow&#xD;
      up period to reveal the clinical, laboratory and radiological response. The procedures are to&#xD;
      be approved by the institutional ethical committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stabilization of oxygen</measure>
    <time_frame>28 days</time_frame>
    <description>at room air more than 90%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital and 28-day mortality</measure>
    <time_frame>28 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative conversion of SARS-CoV- 2 by Day 28</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>INTERVENTION ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin,ribavirin ,nitazoxanide and zinc</intervention_name>
    <description>oral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc</description>
    <arm_group_label>INTERVENTION ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged â‰¥18 years&#xD;
&#xD;
               -  Laboratory-confirmed SARS-CoV- 2 infection&#xD;
&#xD;
               -  Hospitalized patients&#xD;
&#xD;
          -  need reservoir mask for oxygen support&#xD;
&#xD;
          -  need HFNC for oxygen support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mechanical ventilations for oxygen support&#xD;
&#xD;
          -  Inability to take oral medications&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hatem elalfy, MD</last_name>
    <phone>01224790518</phone>
    <email>ELALFY2004@MANS.EDU.EG</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Select A State Or Province</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hatem elalfy</last_name>
      <phone>01224790518</phone>
      <email>elalfy_hatem66@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Hatem Elalfy</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

